Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.640
+0.070 (4.46%)
Oct 20, 2025, 3:21 PM EDT - Market open
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $118.11K in the quarter ending June 30, 2025, a decrease of -78.97%. This brings the company's revenue in the last twelve months to $841.01K, down -34.07% year-over-year. In the year 2024, Aprea Therapeutics had annual revenue of $1.50M with 157.63% growth.
Revenue (ttm)
$841.01K
Revenue Growth
-34.07%
P/S Ratio
11.19
Revenue / Employee
$105,127
Employees
8
Market Cap
9.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
Dec 31, 2023 | 583.23K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
APRE News
- 5 days ago - Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies - GlobeNewsWire
- 6 days ago - Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 7 weeks ago - Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewsWire
- 4 months ago - Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - GlobeNewsWire
- 5 months ago - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewsWire
- 7 months ago - Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - GlobeNewsWire
- 7 months ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire